We want an effective medicine to be there when someone we love needs it. Not almost available. Not something that could have been supplied if arrangements had been made earlier. There, in time to help.
A reserve antibiotic is a medicine kept for infections that other antibiotics cannot reliably treat. Its importance is not measured simply by how often it is prescribed. Sometimes, using it rarely is part of protecting what it can do.
Avoiding unnecessary use helps slow antibiotic resistance: bacteria becoming able to withstand the medicines used against them. Restraint cannot guarantee that a drug will remain effective forever. But it matters.
So does treatment. When a reserve antibiotic is the right medicine, protecting it means using it responsibly—not withholding it from someone who needs it.
The difficulty appears in how we pay.
If a maker earns revenue for each dose sold, fewer doses mean less sales income. Yet keeping the medicine available still takes work: maintaining production capacity, checking quality, sustaining a dependable supply. Those obligations do not disappear during a quiet year.
Successful restraint can therefore reduce the very income that helps support continued supply. That does not make a supplier a villain, or mean low sales must lead to a shortage. It reveals a mismatch between what the payment counts and what we need.
Readiness has value before there is a sale.
One possible arrangement would pay for that value directly. A health system could pay a regular amount for dependable availability, rather than making the supplier’s income depend chiefly on the number of doses sold. In return, the supplier would have clear obligations: maintain quality, keep agreed supplies available and deliver within agreed times.
The payment would support being ready. It would not be a request to prescribe more.
Such an arrangement would still have to prove its worth. The price would need scrutiny. Supply commitments would need checking. Careful prescribing would remain essential, and patients would need timely access when treatment was indicated. A fee alone is not preparedness.
But this is a different way to frame the task. Instead of relying chiefly on consumption to finance continued supply, we could make dependable availability something we explicitly pay for.
We hope the person we love never needs that medicine. We want it ready if they do.
There is room to build a payment system around both wishes.